Physician profile
Naseem Labue
NPI 1063891679
$2,467.62
in general payments reported to CMS, 2019-2025
27 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $216 · 2021: $241 · 2022: $221 · 2023: $309 · 2024: $432 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.32 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $285.97 | 2019-2020 | |
| Lilly USA, LLC | $268.12 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $206.79 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $192.25 | 2024 | |
| Astellas Pharma US INC | $185.87 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.96 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $74.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.53 | 2019-2025 | Trintellix |
| Amgen INC. | $60.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.19 | 2019 | |
| Merck Sharp & Dohme LLC | $54.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.17 | 2022 | |
| Idorsia Pharmaceuticals US INC | $31.50 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $30.84 | 2022-2023 | Arexvy, Shingrix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.64 | 2021-2022 | |
| Nalpropion Pharmaceuticals LLC | $21.68 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.44 | 2022 | |
| Tempus Ai, INC | $16.97 | 2024 | |
| Dynavax Technologies Corporation | $16.35 | 2025 | Heplisav-B |
| Shire North American Group INC | $16.14 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.97 | 2025 | Rexulti |
| Mylan Specialty L.P. | $15.50 | 2023 | Yupelri |
| Shield Therapeutics INC | $15.04 | 2022 | |
| Exact Sciences Corporation | $14.98 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $14.83 | 2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $13.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naseem Labue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.